⌘K
Loading ticker…
As of 2026-08-24, Spyre Therapeutics, Inc. Common Stock (SYRE) has a 3-month relative strength percentile of 92 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 96. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.5%, relative volume 0.75×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
SYRE is in a stage 2 uptrend, week 12. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 9.4% / 81.1%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
SYRE is held by 31 ETFs as of May 2026. Top owner: VTWO at 0.16% weight, $28M notional. Top 3 carry $65M.
Held by 59 ETFs · $465M across latest filings · largest weight 6.41% (LFSC).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.16% | $28M | +0.06 pp |
| SCHASchwab U.S. Small-Cap ETF | 0.12% | $26M | +0.05 pp |
| VHTVanguard Health Care ETF | 0.06% | $11M | +0.03 pp |
| LFSC | 6.41% | $7M | +2.00 pp |
| SBIO | 3.68% | $6M | +1.52 pp |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| VTWG |
| 0.21% |
| $3M |
| +0.08 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.01% | $3M | — |
| VFMO | 0.16% | $3M | new |
| DWAS | 0.56% | $2M | +0.10 pp |
| ESML | 0.10% | $2M | new |
Showing 10 of 31 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SYRE Jan avg: 5.59% median: -1.25% win: 33% σ: 12.84% n: 3 2023-11-29 → 2026-07-31 | SYRE Feb avg: 8.70% median: 5.91% win: 67% σ: 24.52% n: 3 2023-11-29 → 2026-07-31 | SYRE Mar avg: 12.47% median: 17.27% win: 67% σ: 28.47% n: 3 2023-11-29 → 2026-07-31 | SYRE Apr avg: 9.69% median: -5.61% win: 33% σ: 33.03% n: 3 2023-11-29 → 2026-07-31 | SYRE May avg: 1.62% median: 0.33% win: 67% σ: 3.72% n: 3 2023-11-29 → 2026-07-31 | SYRE Jun avg: -4.66% median: -2.03% win: 33% σ: 26.86% n: 3 2023-11-29 → 2026-07-31 | SYRE Jul avg: 13.70% median: 13.36% win: 100% σ: 3.12% n: 3 2023-11-29 → 2026-07-31 | SYRE Aug avg: 0.86% median: 0.86% win: 50% σ: 5.21% n: 2 2023-11-29 → 2026-07-31 (current) | SYRE Sep avg: 1.97% median: 1.97% win: 100% σ: 0.46% n: 2 2023-11-29 → 2026-07-31 | SYRE Oct avg: 28.28% median: 28.28% win: 100% σ: 24.98% n: 2 2023-11-29 → 2026-07-31 | SYRE Nov avg: 12.91% median: 22.65% win: 67% σ: 22.30% n: 3 2023-11-29 → 2026-07-31 | SYRE Dec avg: 2.14% median: 9.20% win: 67% σ: 17.80% n: 3 2023-11-29 → 2026-07-31 |